Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer

BACKGROUND: Two randomized clinical trials have demonstrated a survival advantage with enzalutamide over placebo in both docetaxel (D)-pretreated and D-naïve metastatic castration-resistant prostate cancer (mCRPC) patients. Cross-resistance between androgen receptor-directed therapies and taxanes ha...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Nadal, Rosa, Zhang, Zhe, Rahman, Hibba, Schweizer, Michael T., Denmeade, Samuel R., Paller, Channing J., Carducci, Michael A., Eisenberger, Mario A., Antonarakis, Emmanuel S.
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4176523/
https://ncbi.nlm.nih.gov/pubmed/25176007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22874
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items